Company Overview - Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing novel therapies through PLK1 inhibition for various cancers [3] - The company's lead asset, onvansertib, is being evaluated in combination with standard of care (SoC) therapeutics for indications such as RAS-mutated metastatic colorectal cancer (mCRC), metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC) [3] Stock Option Grant - On April 14, 2025, Cardiff Oncology granted non-qualified stock option awards to purchase a total of 35,040 shares of common stock to a new employee [1] - The exercise price for these options is set at $2.79 per share, which matches the closing price of the company's common stock on the grant date [2] - The options will vest over a 4-year period, with 25% vesting on the 1-year anniversary and the remaining shares vesting monthly over the subsequent 36 months, contingent on the employee's continued employment [2]
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)